Singapore is ageing faster than most high-income countries. By the early 2030s, national population projections show roughly one in four residents will be aged 65 or older — a demographic shift that makes cognitive health one of the most consequential longevity variables a working-age Singaporean can actively manage. The gap between “something is noticeably wrong” and “this was detectable years earlier” is where the clinical opportunity lives, and Singapore's polyclinic network is the most practical entry point to close it.
The Lancet Commission on Dementia Prevention, Intervention and Care (Livingston et al., The Lancet, 2020) identified twelve modifiable risk factors — including hypertension, physical inactivity, type 2 diabetes, and social isolation — that collectively account for approximately 40% of dementia cases worldwide. Most of those factors are identifiable at a standard polyclinic visit, via the same cardiovascular and metabolic bloodwork that Screen for Life (SfL), the national screening programme administered by HPB (the Health Promotion Board), already subsidises. The cognitive screening conversation, in other words, does not require a specialist referral to begin.
This article maps the cognitive assessment tools available at Singapore polyclinics, explains what your scores and associated biomarkers actually mean, outlines what the subsidies cover, and details the evidence-ranked steps worth taking once you have the results.
Screening Tests Available at Singapore Polyclinics
Three cognitive assessment instruments are in regular use across Singapore's 24 polyclinics and CHAS (Community Health Assist Scheme) GP clinics. Each measures a different aspect of cognitive function, and each carries a different clinical sensitivity for early-stage decline.
Abbreviated Mental Test (AMT)
The AMT is a 10-item screen covering orientation, memory, and temporal awareness. It takes roughly two minutes to administer. A score of 8–10 is within the normal range; 7 or below indicates a need for further assessment. The AMT is designed for rapid primary-care use, not detailed cognitive profiling — it reliably identifies gross impairment but misses the mild cognitive impairment (MCI, a measurable but not yet functionally disabling decline in one or more cognitive domains) that often precedes more significant decline by years. If you receive only an AMT at a routine chronic disease review, you have a floor, not a ceiling.
Mini-Mental State Examination (MMSE)
The MMSE is a 30-point test assessing orientation, registration, attention and calculation, recall, and language. Standard clinical classification: 24–30 normal; 18–23 mild impairment; below 18 moderate-to-severe impairment. The MMSE has been the dominant cognitive screen in primary care for four decades, but research suggests it is substantially less sensitive than the MoCA for detecting MCI — particularly in individuals with higher educational attainment, where a ceiling effect can mask early decline that a harder task would expose.
Montreal Cognitive Assessment (MoCA)
The MoCA is a 30-point instrument that adds visuospatial, executive function, and abstract reasoning tasks absent from the MMSE. Nasreddine et al., writing in the Journal of the American Geriatrics Society (2005), reported the MoCA detected MCI with 90% sensitivity compared with the MMSE's 18% sensitivity in the same patient population — a clinically significant difference for early-detection purposes. Standard classification: 26–30 normal; 18–25 mild cognitive impairment; below 18 moderate-to-severe impairment. Not all polyclinics administer the MoCA as a default; it is more typically deployed when an AMT or MMSE raises a concern, or when a patient proactively requests a more detailed cognitive baseline. If early detection is your goal, it is worth requesting the MoCA by name.
Which instrument you receive at a given visit depends on clinical context and the clinician's judgement. For a longevity-oriented baseline — not because you have symptoms, but because you want a trajectory you can track — ask specifically for a MoCA. It is within standard primary-care practice and does not require a referral.
READ ALSO: Executive Function and the Ageing Singapore Brain: What the Research Shows
Understanding Your Results: Standard Clinical Ranges vs. Longevity-Optimised Ranges
A cognitive test score is a snapshot of today. The metabolic and cardiovascular markers measured at the same visit — blood pressure, fasting glucose, HbA1c (glycated haemoglobin, a measure of average blood sugar over 8–12 weeks), and lipid levels — often predict cognitive trajectory more reliably than a single test score. The standard clinical thresholds are set for disease detection; longevity-optimised ranges are set for prevention. The gap between them is where the practical work sits.
| Biomarker | Standard Clinical Range | Longevity-Optimised Range | The Gap |
|---|---|---|---|
| Systolic blood pressure | <140 mmHg (MOH hypertension threshold) | <120 mmHg | 20 mmHg where silent vascular damage to cerebral small vessels accumulates over years before any clinical flag is raised |
| Fasting glucose | <6.0 mmol/L (pre-diabetes threshold) | <5.0 mmol/L | The 5.0–6.0 mmol/L range is associated with measurably higher cognitive risk before a formal diabetes diagnosis is made |
| HbA1c | <6.5% (diabetic diagnostic threshold) | <5.4% | HbA1c values above 5.4% are associated with increased rates of hippocampal atrophy (volume reduction in the brain's primary memory-consolidation region) in prospective cohort data |
| LDL cholesterol | <3.4 mmol/L (general clinical cutoff) | <2.0 mmol/L (cardiovascular longevity target) | Cumulative vascular burden on the brain begins accruing well below the clinical disease threshold; the standard cutoff was not designed with cognitive longevity in mind |
The blood pressure gap is the most action-ready of these. The SPRINT MIND investigators, reporting in JAMA (2019), found that intensive blood pressure management targeting a systolic below 120 mmHg reduced the incidence of mild cognitive impairment by 19% compared with standard treatment targeting below 140 mmHg, in a trial of over 9,300 adults with elevated cardiovascular risk. The research confirms that blood pressure managed to a longevity-optimised target, not merely a disease-prevention threshold, has a measurable effect on cognitive outcomes.
For glucose, the mechanism runs through the brain's insulin-signalling pathway. The National Institute on Aging and multiple prospective cohort analyses demonstrate that even within the conventionally “normal” fasting glucose range, higher values correlate with worse cognitive performance trajectories. Insulin resistance impairs the brain's ability to use glucose as fuel efficiently — a pathway sometimes described as metabolic cognitive impairment — and it begins accumulating damage before any clinical threshold is crossed.
READ ALSO: HbA1c, Insulin Resistance, and Cognitive Decline: A Singapore Primer
CHAS, HPB, and Polyclinic Screening Costs
Singapore's subsidised primary-care infrastructure is, for cognitive longevity purposes, substantially underused. Screen for Life, administered by HPB and delivered at polyclinics and CHAS GP clinics, covers blood pressure, blood glucose, and lipid panel testing for eligible Singaporeans and permanent residents. The per-visit cost at a polyclinic is $5 SGD (2026) for Singapore citizens; CHAS (Community Health Assist Scheme) cardholders receive the same SfL screen at $0 SGD, with the CHAS scheme providing subsidised outpatient care at participating GP and polyclinic settings for Singaporeans within qualifying household income bands — check MOH (the Ministry of Health) for current eligibility thresholds, as these are updated periodically.
Cognitive testing itself — the AMT, MMSE, or MoCA — does not sit within the Screen for Life panel as a standard component. In practice, a polyclinic physician will typically administer a brief cognitive screen when a patient is aged 65 or older, has chronic conditions associated with cognitive risk, or reports memory concerns. If none of those triggers apply to your clinical profile but you want a cognitive baseline, you can request an assessment during your consultation; most polyclinic physicians will accommodate this within the same appointment, particularly if you frame it explicitly as a longevity baseline.
For a more detailed neuropsychological workup — a full battery assessing multiple cognitive domains over 90–120 minutes — the public hospital pathway is accessible via a polyclinic referral. Memory clinics at restructured hospitals such as Tan Tock Seng Hospital and National University Hospital operate under subsidised rates at B2 and C class; out-of-pocket costs at B2 class with Medisave usage typically range from $50–$150 SGD (2026) for an initial memory clinic consultation, depending on CHAS subsidy tier. A full neuropsychological battery privately ranges from $400–$800 SGD (2026). Verify current rates directly with the institution or via MOH's hospital bill size reference tool, as figures shift with subsidy policy changes.
READ ALSO: Using Screen for Life Results for Longevity Planning Beyond Disease Detection
How Cognitive Screening Connects to Modifiable Risk Factors
The Lancet Commission's figure — 40% of dementia cases linked to modifiable risk factors — deserves more clinical weight than it typically receives. In Singapore's population, three of those factors carry particular prevalence. Hypertension affects roughly 1 in 3 adults aged 30–69 according to HPB national health survey data. Type 2 diabetes affects approximately 1 in 9 Singaporean adults, one of the higher rates in Asia, per MOH national health statistics. Physical inactivity — defined as fewer than 150 minutes per week of moderate-intensity activity — is the third.
The vascular pathway is the most mechanistically direct. Hypertension damages cerebral small vessels — the fine capillary network that supplies the brain's white matter — gradually reducing blood flow and oxygenation to areas responsible for processing speed, executive function, and memory consolidation. This process is silent for years, reflected in imaging findings but not in any single clinic visit's cognitive test score. Blood pressure at the longevity-optimised range, not merely below the hypertension diagnosis threshold, is what protects that capillary network over time.
The research suggests that physical activity is the most consistently supported single modifiable factor for cognitive preservation across the available evidence base. The FINGER trial (Ngandu et al., The Lancet, 2015), a randomised controlled trial of 1,260 adults at elevated dementia risk, showed that a two-year multidomain intervention combining aerobic exercise, nutritional guidance, cognitive training, and vascular risk management improved or maintained composite cognitive performance compared with general health advice. The aerobic exercise component was the most consistently active across subgroup analyses. In Singapore's climate — where 31°C heat and 80% humidity make midday outdoor exercise physiologically demanding — this translates practically to morning Zone 2 sessions (sustained aerobic exercise at roughly 60–70% of maximum heart rate) in parks before 8 a.m., or indoor classes at community centres.
Sleep is the frequently missing variable. The research confirms that chronic short sleep — below seven hours per night — accelerates amyloid-beta accumulation in the brain, the protein aggregate associated with Alzheimer's pathology (Lucey et al., Science, 2019; covered by NIH Research Matters). A polyclinic visit will not include a formal sleep quality screen as standard — but the question is worth raising, because poor sleep and the cardiovascular risk factors that Screen for Life does measure often co-occur and amplify each other's cognitive effects.
READ ALSO: Sleep Quality and Cognitive Longevity in Singapore: The Overlooked Protocol
Evidence-Tiered Steps After Your Screening
The following steps are ordered by evidence strength, with the tier visible in the verb.
1. Address blood pressure to a longevity-optimised target, not just a disease threshold. The research confirms that a systolic target below 120 mmHg reduces the rate of mild cognitive impairment compared with the standard below-140 mmHg target (SPRINT MIND, JAMA, 2019). Raise this target explicitly with your clinician — it often requires either a medication review or a substantive upgrade to lifestyle modifications, and the standard disease threshold is insufficient for cognitive longevity purposes.
2. Bring fasting glucose below 5.0 mmol/L where possible. The research suggests that reducing fasting glucose within the “normal” range slows the metabolic cognitive impairment pathway. A practical starting point at the hawker centre: replace white rice with brown rice where available, choose kopi-O over teh tarik, and treat the fasting glucose number as a cognitive metric, not merely a diabetes-risk metric. Any medication adjustments require clinician guidance; consult your clinician before acting on this.
3. Sustain aerobic exercise at Zone 2 intensity for a minimum of 150 minutes weekly. The research confirms, across the FINGER trial and subsequent replication studies under the World Wide FINGERS initiative, that multidomain interventions anchored in aerobic exercise preserve cognitive performance in adults at elevated risk. The WHO's dementia risk-reduction guidelines align with this evidence base. Consult your clinician before beginning a new exercise programme if your cardiovascular markers are outside range.
4. Request a repeat MoCA in 12 months. A trajectory over two or more assessments is diagnostically more useful than any single score. A MoCA of 27 at age 45, stable at 27 twelve months later, is reassuring. A MoCA of 27 dropping to 24 over the same period merits formal review regardless of where either number sits relative to clinical cutoffs.
5. Raise sleep quality with your polyclinic physician if cardiovascular risk markers are elevated. Preliminary research indicates that targeted sleep interventions may reduce amyloid accumulation trajectory, but the human trial evidence base is still developing. The practical and zero-cost step is to include sleep duration and quality in your chronic disease review — a conversation standard appointments rarely initiate.
Building Your Longevity System: The 30-Day Biohacking Starter Guide
This article covers one piece of the system. The 30-Day Biohacking Starter Guide covers all of it, with a day-by-day protocol built specifically for Singapore.
Frequently Asked Questions
How do I request a cognitive screening at a polyclinic?
Book an appointment at any polyclinic via the HealthHub app or the SingHealth or NHG patient portals. At the appointment, tell the physician you would like a cognitive assessment as part of your review. If you are under 65 and do not have a chronic disease flag, frame it as a longevity baseline — most polyclinic physicians will accommodate this within the same consultation. If you have a specific concern about memory changes, describe those directly; this typically triggers a more structured assessment or a memory clinic referral. Request the MoCA by name if you want the more sensitive instrument.
Is there an age minimum for cognitive screening at a polyclinic?
There is no formal minimum age for requesting a cognitive assessment. Screen for Life eligibility for metabolic screening (blood pressure, glucose, cholesterol) begins at 18 for specific risk groups and at 40 broadly. Cognitive screening instruments are most commonly used in primary care for patients aged 60 and above, but a younger individual with risk factors — a first-degree family history of early-onset dementia, hypertension diagnosed before 40, or persistent cognitive symptoms — can request an assessment at any age.
What is the difference between a normal MoCA score and a longevity-optimised baseline?
The clinical threshold for a “normal” MoCA is 26 out of 30. For longevity planning, a score of 28–30 represents a more useful starting baseline — not because 26 is clinically alarming, but because a score of 26 at age 42 leaves limited headroom before the clinical concern threshold is reached as age-related changes accumulate over two decades. A baseline of 28–30 also makes any downward trajectory in future re-tests easier to detect and act on early.
Does Screen for Life cover cognitive testing?
Screen for Life does not include a cognitive test as a standard component; it covers metabolic and selected cancer screenings. However, the cardiovascular and metabolic markers it measures — blood pressure, HbA1c, fasting glucose, lipid panel — are direct inputs into cognitive trajectory via the vascular and metabolic pathways described above. A Screen for Life result showing borderline hypertension and a fasting glucose of 5.6 mmol/L is, in functional terms, a cognitive risk result, even though the word “cognitive” appears nowhere on the report.
How much does a full memory clinic assessment cost through the public system?
A polyclinic referral to a public hospital memory clinic grants access to B2 or C class subsidised rates. Out-of-pocket costs at B2 class with Medisave usage typically range from $50–$150 SGD (2026) for an initial consultation, depending on CHAS subsidy tier and clinical complexity. A comprehensive neuropsychological battery — covering multiple cognitive domains over 90–120 minutes — ranges from $400–$800 SGD (2026) in the private sector. These figures are approximate; verify current rates directly with the institution or via the MOH hospital bill size tool before your appointment.
